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Objectives: The WHO recently recommended the use of a new first-line ART containing dolutegravir. We investi-
gated the efficacy of NRTI backbones (tenofovir or abacavir with a cytosine analogue) in low- and middle-
income countries where there is significant prior exposure to antiretrovirals and drug resistance to NRTIs.
Methods: Within the treatment-as-prevention study in South Africa, we selected participants with available next-
generation sequencing (NGS) data for the HIV-1 pol gene at trial entry; they were either ART initiators (n"1193) or
already established on ART (n"94). NGS of the HIV-1 pol gene was carried out using MiSeq technology; reverse
transcriptase drug resistance mutations (DRMs) were detected at 5% (DRM5%) and 20% (DRM20%) for all 1287 par-
ticipants. Genotypic susceptibility was assessed using the Stanford HIVDB resistance interpretation algorithm.
Results: NRTI DRM20% and DRM5% were detected among 5/1193 (0.4%) and 9/1193 (0.8%) of ART initiators,
respectively. There was tenofovir exposure in 73/94 (77.7%) of those established on ART, with full susceptibility
to abacavir in 57/94 (60.6%) and 56/94 (59.6%) for DRM20% and DRM5%, respectively, while 67/94 (71.3%) and
64/94 (68.1%) were fully susceptible to tenofovir, respectively. The differences between tenofovir and abacavir
were not statistically significant at the 20% or 5% variant level (P"0.16 and 0.29, respectively). NGS detection of
variants at the 5% level increased detection of K65R in both naive and treated groups. One of 607 integrase
sequences carried a DRM20% (Q148R).
Conclusions: Dolutegravir with a cytosine analogue plus tenofovir or abacavir appears to have similar efficacy in
South Africans naive to ART. NGS should be considered in HIV drug resistance surveillance.
Introduction
Countries such as South Africa are implementing a universal test-
and-treat strategy recommended by the WHO, therefore increas-
ing the number of people eligible for ART. This policy may lead to
higher levels of acquired drug resistance1,2 and transmitted drug
resistance3 and compromised ART efficacy in a proportion of
patients.4,5 For this reason, a robust, cheap and well tolerated
fixed-dose combination (FDC) first-line therapy, with a high genetic
barrier, is highly desirable. Although NNRTI-based regimens were
efficacious, the low genetic barrier to resistance has resulted in an
increasing level of pretreatment drug resistance (PDR) to NNRTIs
across low- and middle-income countries (LMICs), compounded
by the use of thymidine analogues (TAs) prior to availability of
tenofovir-based NRTI backbones.6 In response to rising PDR in
LMICs, the WHO recommended in 2017 the use of a novel anti-
retroviral, dolutegravir, a second-generation integrase strand
transfer inhibitor (INSTI), in countries with a PDR level .10%.7
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Cheaper to manufacture, dolutegravir appears to be a good candi-
date with a high genetic barrier to resistance based on first-line
ART studies in northern countries with predominantly subtype B
viruses.8–10
However, the NRTI backbone needs to be carefully chosen as
pretreatment NRTI resistance in ART-naive/prior-ART-exposed
individuals may compromise the successful implementation of
dolutegravir-based first-line therapy.11 Moreover, if its implemen-
tation is based on a public health approach, some patients already
on efavirenz-based first-line ART may be switched to the new rec-
ommended first-line therapy, without prior monitoring of virologic-
al suppression status. This raises the very real possibility that
patients with virological failure and extensive NRTI resistance
mutations1 could be switched to dolutegravir-based ART.
So far, only the FDCs of abacavir/lamivudine/dolutegravir12 and
since April 2018 tenofovir/lamivudine/dolutegravir8 have been
manufactured and are available. In 2009, Sax et al.13 observed a
shorter time to virological failure and to first adverse event in peo-
ple starting ART with an abacavir/lamivudine backbone, compared
with tenofovir/emtricitabine, in combination with either efavirenz
or atazanavir. The FDC of tenofovir/emtricitabine/efavirenz has
been available since 2010 and recommended as first-line therapy.
Wide-scale use of the same NRTI backbone for previous NNRTI and
future INSTI-based regimens has raised concerns regarding activ-
ity in those patients with PDR or ongoing viral failure at the time of
switch from efavirenz to dolutegravir.
We investigated drug resistance to NRTIs, NNRTIs and INSTIs in
the ANRS 12249 treatment-as-prevention (TasP) trial in ART re-
initiators/initiators, as well as in people failing their first-line ART
enrolled in the trial, in order to understand whether abacavir- or
tenofovir-based backbones would be more active.
Methods
Study design and setting
The ANRS 12249 TasP trial was a cluster-randomized trial implemented in
22 clusters (2%11) in the Hlabisa sub-district in rural KwaZulu-Natal, South
Africa, from March 2012 to June 2016. There were 1000 individuals
16 years residing in each cluster with an HIV prevalence of30%. The full
trial protocol has been described previously; participants residing in the
intervention clusters were offered ART after HIV diagnosis, regardless of
their CD4 counts, whereas participants in control clusters were offered ART
according to the prevailing South African guidelines (i.e. CD4 count
,350 cells/mm3 in March 2012, then ,500 cells/mm3 from January
2015).14
Study population
Participants attending the trial clinics were either ART naive at entry into the
trial or already established on ART prescribed through the Hlabisa HIV treat-
ment and care programme. All individuals were asked to complete study
questionnaires and provide plasma samples at their first trial clinic visit.
Plasma samples were used for viral load (VL) testing, using the Abbott
RealTime HIV-1 m2000rt (Abbott Molecular Inc., Des Plaines, IL, USA), as
well as for Sanger drug resistance testing in the Africa Health Research
Institute diagnostic laboratory when clinically indicated.
Next-generation sequencing (NGS)
NGS was used to characterize HIV pol from participants’ plasma samples
with a VL 1000 copies/mL, adapting a protocol that was previously
described by Gall et al.15 Briefly, RNAs were extracted from 1 mL of plasma,
using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) and were
eluted in 60lL of elution buffer. The near-full HIV genome was amplified
with four subtype-C-specific primer pairs, generating four overlapping
amplicons of 2.1, 2.3, 2.2 and 3.9 kb. DNA concentrations of amplicons were
quantified with the Qubit dsDNA HS Assay Kit (Invitrogen, Carlsbad, CA,
USA). Diluted at 0.2 ng/lL each, amplicons were pooled equimolarly and
prepared for the library using the Nextera XT DNA Library preparation and
the Nextera XT DNA sample preparation index kits (Illumina, San Diego, CA,
USA), following the manufacturer’s protocol. The runs comprised a total of
96 samples, including three controls: 1 negative sample, 1 inter-run sample
and 1 intra-run sample. If amplification or sequencing failed for the pol re-
gion of the HIV genome, samples were re-amplified with primers that par-
tially covered the pol gene, excluding the integrase, and were sequenced in
a 386-sample run, with the same controls as the 96-sample run. The intra-
run and inter-run controls were used to assess the reproducibility and
accuracy of our method (n"29). The mean identity of the consensus
sequences derived for each duplicate was 99.81% (SD"0.35%). The mean
difference between the SNP frequencies, detected from 0.2% to 100%, was
1.4% (SD"2.5%); therefore, we set with confidence our detection level of
minority variants at 5%.
Read assembly was performed using Geneious 10.0.6 software;16 brief-
ly, reads between 100 and 300 bp were selected and those with Phred
scores,30 were excluded. The sequences were trimmed up to 10 bp from
50 and 30 bp at the 30 end and mapped against a subtype C reference se-
quence (AF411967) annotated for WHO surveillance of drug resistance
mutations (DRMs).17 Minority variants between 5% and 20% were included
when they were also detected by a BaseSpace application, MiCall.18 DRMs
in the reverse transcriptase and integrase were detected at 20% (DRM20%)
and 5% (DRM5%) levels of detection.
DRM penalty scores and resistance interpretation were estimated
using the Stanford HIV Drug Resistance database (https://hivdb.stan
ford.edu/) for the following drugs: abacavir, cytosine analogues (lamiv-
udine and emtricitabine), zidovudine, tenofovir, efavirenz/nevirapine
and dolutegravir. The mutation scores were classified as follows: 0–9,
susceptible; 10–29, low-level resistant; and 30, resistant. According to
the REGA algorithm V10.0.0, the genotypic susceptibility score (GSS)
was calculated for the entire abacavir/lamivudine/dolutegravir or teno-
fovir/lamivudine/dolutegravir regimens; a GSS score 3 and 2 repre-
sents full susceptibility to the regimen amongst ART initiators and
ART-exposed persons, respectively.19
Ethics
The trial was approved by the Biomedical Research Ethics Committee (BFC
104/11) at the University of KwaZulu-Natal and the Medicines Control
Council of South Africa (ClinicalTrials.gov: NCT01509508; South African
National Clinical Trials Register: DOH-27-0512-3974). All trial participants
gave written consent or witnessed thumbprint informed consent prior to
undertaking any study procedures.
Results
Drug resistance cohort description
Of the 1287 participants with available NGS data for the reverse
transcriptase gene, 1193 were classified as ART initiators [their ART
status was naive (n"1054), their ART status was unknown
(n"106) or they were previously exposed to a prevention of
mother-to-child HIV transmission (PMTCT) regimen (n"33)], while
94 participants were currently exposed to ART (Table 1). Integrase
NGS data were available for 524 ART initiators and 83 ART-exposed
participants.
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Among participants already on ART at trial entry, all were on an
NNRTI-based regimen; 23 were on a TA backbone (zidovudine or
stavudine) for a median time of 57.3 months (IQR 38.7–85.8),
while 71 were on a tenofovir backbone for a median time of
22.4 months (IQR 11.6–37.2). Among people on a tenofovir-based
regimen, 19 were previously on a stavudine-based regimen for a
median time of 49.0 months (IQR 44.3–67.4).
The participants included in our study had a median age of
33 years (IQR 25–44) and most were female (70.5%). The over-
all median of CD4 count was 427 cells/mm3 IQR (247–615) and
was lower among participants already on ART [255 cells/mm3
(IQR 131–485)], while the median VL was 4.6 log10 copies/mL
(IQR 4.0–5.2) and was not different across the different
subgroups.
DRMs
Among ART initiators, 116/1193 (9.7%) had at least one reverse
transcriptase inhibitor (RTI) DRM20%, while 54/94 (57.4%) partici-
pants who were on ART had detectable RTI DRM20%. When minor-
ity resistant variants were assessed, 152/1193 (12.7%) of ART
initiators and 57/94 (60.6%) of ART-exposed participants had RTI
DRM5%.
Among all DRM20% detected in ART-initiator participants
(n"148), 137/148 (92.6%) belonged to the NNRTI class, mostly
represented by the K103N/S mutations (n"88/137, 64.2%), while
11/148 (7.4%) were NRTI mutations (Figure 1a). While no major
mutation was described for dolutegravir resistance, we found
some accessory integrase mutations in 98/524 (18.7%), such as
L74I/M (n"81/98, 82.7%), T97A (n"8/98, 8.2%) and E157Q
(n"5/98, 5.1%), and more sporadically E138D/K (n"2), V151I
(n"1) and G163R (n"1). The main mutations found in the NRTI
class were M184V (n"4/11, 36.4%) associated with cytosine ana-
logues and abacavir resistance, and the main TA mutation (TAM)
T215S in its revertant form (n"3/11, 27.3%). The K65R mutation
was found in one participant (n"1/11, 9.1%). When DRM5% were
assessed, double the number of NRTI mutations were found
(n"22), mostly represented by K65R (n"4/22, 18.2%) and the
TAMs D67N and K219EQ (Figure 1b). Nine additional integrase
DRM5% were found, mostly L74M (n"5).
Among ART-exposed participants, a total of 217 DRM20% were
detected and were equally distributed between the NRTI (104/
217, 47.9%) and the NNRTI (113/217, 52.1%) classes. Fifteen par-
ticipants had integrase DRM20% (15/83, 18.1%), including Q148R
conferring low-level resistance to dolutegravir, and some acces-
sory integrase mutations were also found: L74I/M (n" 12/15,
80.0%), E157Q (n"1) and G163R (n"1). No patients had a major
dolutegravir resistance mutation. Among NRTI DRMs, M184IV was
the most prevalent (n"36/104, 34.6%), followed by K65R (20/
104, 19.2%) (Figure 1c). K65R was detected in 18/72 (25.0%) and
2/17 (11.8%) participants who were on a tenofovir- and stavudine-
based regimen, respectively. TAMs represented 14.4% of the DRMs
(n"15/104); they belonged exclusively to the TAM-2 pathway
and were found among nine participants who were previously or
currently treated with TAs, with the exception of two participants
who initiated ART with a tenofovir-based regimen.
Twenty-two more NRTI DRM5% were detected, mostly repre-
sented by the TAM-2 mutations in addition to two mutations from
the TAM-1 pathway (M41L and L210W). Notably, two additional
K65R mutations were detected at the 5% as compared with the
20% variant threshold (Figure 1d). Three additional participants
had integrase DRM5%.
Genotypic antiretroviral susceptibility
When resistance was detected at a 20% variant level, all ART initia-
tors with available consensus sequence covering the entire inte-
grase (n"524) were fully susceptible to dolutegravir. Only 5
participants out of 1193 (0.4%) had low- to high-level NRTI resist-
ance, while 115 had resistance to NNRTIs (9.6%) (Figure 2). At a
variant level of 5%, more participants had RTI resistance detected
among ART initiators; 9/1193 participants had NRTI resistance
Table 1. Demographic and clinical data of study cohort
n
Previous
ARTa
Female
(%)
Age (years),
median (IQR)
CD4 count
(cells/mm3),
median (IQR)
VL (copies/mL),
median (IQR)
Log10 VL,
median
(IQR)
Time on ART
(months),
median (IQR)
All participants 1287 NA 70.5 33 (25–44) 427 (247–615) 36961 (9253–153947) 4.6 (4.0–5.2) NA
ART initiators 1193 NA 71.1 32 (25–45) 439 (262–625) 35020 (9095–151406) 4.5 (4.0–5.2) NA
ART naive 1054 NA 70.6 33 (25–45) 431 (256–618) 38016 (9370–159908) 4.6 (4.0–5.2) NA
ART status unknown 106 NA 67.0 32 (25–46) 505 (320–657) 21269 (8165–69843) 4.3 (3.9–4.8) NA
previously exposed to
a PMTCT regimen
33 NA 100 28 (24–34) 539 (399–675) 17210 (4758–101000) 4.2 (3.7–5.0) NA
ART exposed 94 NA 62.8 34 (28–41) 255 (131–485) 59660 (14166–180933) 4.8 (4.2–5.3) 40.8 (21.7–69.4)
current ART d4T/ZDV 21 no 66.7 39 (32–44) 198 (154–416) 114132 (51488–190124) 5.1 (4.7–5.3) 67.9 (50.0–88.5)
2 yes 0.0 60 (57–62) 208 (199–218) 135509 (109888–161129) 5.1 (5.0–5.2) 25.5 (19.4–31.6)
current ART TDF 52 no 63.5 31 (27–38) 355 (203–545) 40428 (8560–143717) 4.6 (3.9–5.2) 24.6 (14.1–36.5)
19 yes 63.2 36 (31–43) 112 (21–189) 77487 (22337–178762) 4.9 (4.3–5.3) 75.4 (69.3–89.7)
d4T, stavudine; ZDV, zidovudine; TDF, tenofovir; NA, not applicable.
aParticipants who had a previous ART regimen with a different NRTI backbone compared with their current ART at time of sampling (either currently
on a stavudine/zidovudine regimen, but had tenofovir in the past, or currently on a tenofovir regimen, but had stavudine/zidovudine in the past).
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(0.8%), while 145/1193 (12.2%) had resistance to NNRTIs
(Figure 2). Whether DRM20% or DRM5% were considered, 99.2% of
ART initiators had full susceptibility (GSS 3) to both dolutegravir-
based regimens. There was no significant difference between the
different ART-initiator sub-groups (ART naive, ART status unknown
and previously exposed to a PMTCT regimen).
Among ART-exposed participants, only one had low-level re-
sistance to dolutegravir (Q148R) among participants with available
consensus sequence covering the integrase (n"83). This
individual had no NRTI mutations. Regarding resistance to
NRTI20%, 57/94 (60.6%) were fully susceptible to abacavir and
cytosine analogues, while 67/94 (71.3%) were fully susceptible to
tenofovir (P"0.16; Figure 2). Accounting for DRM5%, 66.0% and
69.1% of participants were predicted to be fully susceptible (GSS
2) to abacavir- and tenofovir-based dolutegravir regimens,
respectively.
Full susceptibility to zidovudine was found among 92/94
(97.9%). Susceptibility to NNRTIs was compromised for 54/94
Figure 1. DRMs among ART initiators (a and b) and ART-exposed participants (c and d), at 20% (a and c) and 5% (b and d) levels of detection.
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(57.4%). When resistance was detected at 5%, full susceptibility to
abacavir and cytosine analogues was found for 56/94 (59.6%),
while 64/94 (68.1%) were fully susceptible to tenofovir (P"0.29).
Full susceptibility to zidovudine was found among 88/94 (93.6%).
Susceptibility to NNRTIs was compromised for 59/94 (62.8%).
Discussion
In countries hosting large ART programmes with limited treatment
options, it is important to evaluate whether the large-scale imple-
mentation of a new regimen will be effective. Following recent
WHO guidelines,7 South Africa will soon roll out a dolutegravir-
based regimen as first-line ART. Our study aimed to predict
genotypic susceptibility to this new regimen by analysing drug re-
sistance over a large population with diverse ART exposure profiles.
We found that a tenofovir! emtricitabine/lamivudine NRTI back-
bone had similar predicted efficacy to one based on abacavir in
place of tenofovir.
We did not find any major mutations associated with high-level
dolutegravir resistance irrespective of whether individuals were
ART initiators or ART exposed. We did observe Q148R, which is
associated with high-level dolutegravir resistance when accompa-
nied by the G140S/A mutations.20 Indeed, INSTIs are used only for
third-line regimens21 and access to them is still limited in most
African countries due to their cost.9 Using NGS for detecting inte-
grase DRM5% allowed detection of more mutations, which corrob-
orates previous studies in northern countries that have not
reported any low-level substitutions or polymorphisms associated
with decreased susceptibility to dolutegravir,22,23 or decreased
virological response to INSTIs.24 However, the choice of the NRTI
backbone remains crucial, as NRTI resistance mutations may
compromise the full potency of dolutegravir-based regimens.
Dolutegravir monotherapy has been shown to be inferior to triple
drug therapy with dolutegravir,25,26 though dolutegra-
vir! lamivudine may be effective in high-income settings where
resistance testing is done before ART initiation.27 Although some
studies demonstrated that dolutegravir combined with two NRTIs
is still potent despite the presence of NRTI mutations,28,29 it is es-
sential to evaluate which NRTI backbone will be the most
appropriate for combination with dolutegravir as first-line ART in
the context of large-scale ART programmes, such as in South
Africa. Indeed, ongoing virological failure in the absence of effect-
ive VL monitoring is associated with increased prevalence of drug
resistance30 and accumulation of mutations.31 Furthermore,
subtype-specific differential resistance profiles/propensities must
be taken into account, such as the higher prevalence of K65R in
subtype C virological failures.1,32,33
Among ART initiators, including patients who were ART naive,
previously exposed to a PMTCT regimen or for whom the ART sta-
tus could not be clarified, nearly all were fully susceptible to both
abacavir and tenofovir, with NRTI resistance found in just under
1% of the population, at both 20% and 5% levels of detection. In
this specific population, both abacavir and tenofovir would be fully
effective and the level of NNRTI resistance found in our population
(.10%) confirmed the need to move towards INSTI-based regi-
mens. Similarly, dolutegravir regimens with either abacavir or
tenofovir were predicted to be fully active in 99% of ART-naive par-
ticipants. Our data suggest that NGS may not provide greater de-
tection of drug resistance over Sanger sequencing under current
conditions in ART-naive individuals.
Among patients on ART, or those previously exposed to ART, full
susceptibility to abacavir and cytosine analogues was found for
56/94 (59.6%), while 64/94 (68.1%) were fully susceptible to teno-
fovir using the 5% threshold. When accounting for DRM5%, full sus-
ceptibility to both dolutegravir regimens was not different and
below 70%. Significant additional mutations, including K65R, were
observed at the 5% level, but not the 20% level, suggesting NGS
might be useful in treatment-experienced patients.
The higher, but non-statistically significant, level of resistance
to abacavir compared with tenofovir in the context of use of an
FDC containing tenofovir/emtricitabine/efavirenz in this population
might be explained by the high prevalence of the M184IV muta-
tions, selected early in regimen failure by cytosine analogues,
which can also confer partial resistance to abacavir.34 Moreover,
the detection of TAMs, likely resulting from prior use of TAs, can en-
hance the resistance to abacavir in the presence of M184V whilst
susceptibility to tenofovir might be increased.35–38 We found a low
level of resistance to zidovudine among both ART initiators and
Figure 2. Antiretroviral susceptibility among ART initiators and ART-exposed participants at 20% and 5% variant levels by NGS. ARV, antiretroviral;
ABC, abacavir; ZDV, zidovudine; 3TC/FTC, lamivudine/emtricitabine; TDF, tenofovir; EFV/NVP, efavirenz/nevirapine.
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ART-exposed participants despite the detection of TAMs; this is
explained by the fact that most of the TAMs were associated with
M184V and/or K65R, mutations known to increase susceptibility to
zidovudine.39 Therefore, these findings confirm the appropriate
use of zidovudine for second-line PI-based therapy, after first-line
virological failure. Finally, while the tenofovir-selected mutation
K65R confers significant resistance to tenofovir and abacavir,40 its
combination with M184IV actually increases the level of resistance
to abacavir, but decreases resistance to tenofovir.34
The preferable choice of using tenofovir as a backbone can be
guided by clinical benefits: tenofovir has potent anti-HBV activity,41
and given the lack of testing for hepatitis B in most LMICs, where
HIV and HBV prevalence is high, tenofovir is the preferred option,
over abacavir. Secondly, HLA testing for HLA B*5701 is recom-
mended where abacavir use is being considered due to the possi-
bility of hypersensitivity reactions with this allele.42 Although one
study found abacavir to be safe in African children regardless of
HLA status,43 no such study has been conducted in adults.
Abacavir use is preferred over tenofovir in children due to bone
mineral density considerations,44 and therefore based on our data
abacavir would be a suitable alternative to tenofovir if similar pat-
terns of HIV drug resistance are found in ART-treated children
about to initiate dolutegravir-based ART. In adults, tenofovir is con-
traindicated in moderate to severe kidney disease and in patients
with high fracture risk. In an ageing population these conditions
are more likely to occur. Although abacavir has been associated
with increased risk of cardiovascular disease in retrospective
cohorts,45 it is unclear whether this is relevant in black African
populations.
This study was limited by a modest number of treated
patients relative to naive patients. As expected the vast major-
ity of naive participants were susceptible to both NRTIs and
INSTIs. We used predicted activities based on genotypes and
rule-based algorithms. Recent data from second-line studies
have called into question the utility of such algorithms given
better responses to second-line ART in those with more NRTI re-
sistance.46 However, in the setting of second-line NRTI, resist-
ance is likely a surrogate of adherence and a boosted PI is likely
sufficient to suppress virus in the majority of those with high ad-
herence. Therefore, virological outcome studies are clearly
needed to answer the question of impact of resistance to com-
ponents of dolutegravir-containing ART.
We did not explore integrase resistance outside the integrase
gene. Finally, we only genotyped those treated individuals with VL
.1000 copies/mL. Although the WHO has defined virological fail-
ure as two consecutive VL counts of.1000 copies/mL, it is import-
ant to investigate drug resistance and outcomes among patients
on ART with VL between 50 and 1000 copies/mL, as these individu-
als will also likely be switched to new dolutegravir first-line treat-
ment without drug resistance testing.
In conclusion, our data suggest that in LMICs tenofovir and aba-
cavir are predicted to have comparable effectiveness in combin-
ation with dolutegravir in treatment-naive individuals.
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